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Streptococcus pneumoniae is the predominant otitis media pathogen and its prevention through eﬀective vaccination could
diminish childhood illness and antibiotic use. This paper reviews 5 pneumococcal conjugate vaccine (PCV) trials that used otitis
mediaasanendpoint:NorthernCaliforniaKaiserPermanente(NCKP;vaccine,7-valentPCV[PCV7]-CRM);FinnishOtitisMedia
(FinOM; vaccines, PCV7-CRM or PCV7-OMPC); Native American Trial (vaccine, PCV7-CRM); Pneumococcal Otitis Eﬃcacy
Trial (POET; vaccine, 11-valent PCV [PCV11]-PD). For the microbiological endpoint, vaccine eﬃcacy against vaccine-serotype
pneumococcal otitis media was about 60% across trials. Against the clinical endpoint of all episodes, vaccine eﬃcacy was 7%
(PCV7-CRM/NCKP),6%(PCV7-CRM/FinOM),−1%(PCV7-OMPC/FinOM),and−0.4%(PCV7-CRM/NativeAmericanTrial);
34% against ﬁrst episodes of ear, nose, and throat specialist-referral cases (PCV11-PD/POET). Both follow-up through 2 years of
age, for the 5 trials, and long-term follow-up, for PCV7-CRM/NCKP and PCV7-CRM/FinOM, demonstrated greater vaccine
eﬃcacy against recurrent AOM and tympanostomy-tube placement, suggesting that vaccination against early episodes of AOM
may prevent subsequent episodes of complicated otitis media. Although study designs varied by primary endpoint measured, age
atfollow-up,sourceofmiddle-earﬂuidforculture,caseascertainment,andtypeofrandomization,eachclinicaltrialdemonstrated
vaccine eﬃcacy against microbiological and/or clinical otitis media.
1.Introduction
Otitis media is commonly an acute infection of childhood
that is most prevalent in children during their ﬁrst years of
life. Otitis media leads to substantial healthcare costs related
to physician visits, antibiotic expenditures, and, for compli-
c a t e dc a s e s ,s u r g i c a lp r o c e d u r e ss u c ha st y m p a n o s t o m y - t u b e
placement. Otitis media is also a major factor in antibiotic
use and the expansion of antibiotic resistance. Prior to the
advent of an eﬀective vaccine against the pneumococcal
serotypes associated with otitis media, approximately two-
thirds of children in the USA, for example, experienced at
least 1 episode of otitis media, and almost 1 in 6 children
experienced 3 or more episodes of otitis media in their
ﬁrst years of life. In vaccine clinical trials in the USA and
Europe, where acute otitis media (AOM) was deﬁned as
the presence of a visibly abnormal tympanic membrane
suggesting middle-ear eﬀusion plus at least one sign of acute
infection (e.g., fever), the rates of AOM episodes in control
groups generally ranged from 1.2 to 1.8 per child per year
(PCPY) in the ﬁrst 2 years of life [1–4]. Identiﬁcation of
the source of infection by tympanocentesis conﬁrms the
diagnosis of AOM, but, outside of clinical trials, most AOM
is diagnosed clinically based on signs and symptoms without
conﬁrmatory culture.
When there is microbiological conﬁrmation that AOM
is caused by bacteria, the principal isolates are Strepto-
coccus pneumoniae, Haemophilus inﬂuenzae,o rMoraxella
catarrhalis with small contributions from Staphylococcus
aureus or Group A Streptococcus [2, 5, 6]. The most
commonlyidentiﬁedpathogenisS.pneumoniaewhich,prior
to adoption of the 7-valent pneumococcal conjugate vaccine
(PCV7),wasisolatedbymyringotomyinapproximatelyone-
third to half of all cases [2, 5, 6]. Although more than 902 International Journal of Otolaryngology
serotypesofS.pneumoniaehavebeenidentiﬁed[2],alimited
number is associated with the majority of pneumococcal
illness [7]. In a review of clinical data published between
January 1970 and June 2008, the S. pneumoniae serotypes
most frequently associated with AOM were 6A, 6B, 14, 19A,
19F, and 23F [8].
Three pneumococcal conjugate vaccine candidates were
studied in clinical trials to assess eﬃcacy against otitis media.
The PCV7 vaccine targets the seven serotypes, 4, 6B, 9V, 14,
18C, 19F, and 23F, each individually conjugated to cross-
reactive material (CRM197), the nontoxic diphtheria toxin
analogue (PCV7-CRM; Pﬁzer [Philadelphia, PA, USA]) [2,
7]. An investigational vaccine containing the same seven S.
pneumoniae serotypes as PCV7-CRM, but conjugated to a
meningococcal outer-membrane protein complex (PCV7-
OMPC;Merck[WestPoint,PA,USA]),alsounderwentclini-
caldevelopment,butitiscurrentlynotlicensed[9].Likewise,
an investigational 11-valent PCV containing serotypes 1, 3,
4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, each conjugated
to a cell-surface protein of H. inﬂuenzae (PCV11-PD;
GlaxoSmithKline [Rixensart, Belgium]), underwent clinical
development but was not submitted for licensure [4]. The
seven serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, which
are found in each formulation, account for 60% to 80%
of the serotypes that commonly cause pneumococcal AOM,
and also account for most of the antibiotic-resistant S.
pneumoniae serotypes [2, 7, 14].
Five clinical trials tested these PCV candidates, and this
paper reviews trial design and methods, the control group,
eﬃcacy endpoints, and results against otitis media as an
endpoint. These trials diﬀered in important aspects that will
be considered, including the primary endpoint measured,
age at follow-up, source of middle-ear ﬂuid (MEF) for
culture, case ascertainment, and type of randomization. As
well as diﬀerences in methodology, the studies also diﬀered
by characteristics of the control group, including rate of
otitis media reported from the control group, the underlying
prevalence of S. pneumoniae AOM in the control group, and
the proportion of vaccine-type AOM episodes in the control
group. Clinical trial results will be recapitulated, both for the
clinical trials and long-term follow-up.
2. Methods
The safety and eﬃcacy of PCV7-CRM was investigated in
two individually randomized, clinical trials—the Northern
California Kaiser Permanente (NCKP) Vaccine Trial and
the Finnish Otitis Media (FinOM) Vaccine Trial—and
in a community-randomized clinical trial among Native
American (Navajo and White Mountain Apache) children
[2, 3, 10, 15]. PCV7-OMPC was investigated as an arm
of the FinOM study [9]. PCV11-PD was studied in the
individually randomized Pneumococcal Otitis Eﬃcacy Trial
(POET) [4]. Table 1 summarizes the key features of the trials
[2–4, 9, 10, 12, 15].
Vaccine eﬃcacy in the trials with otitis media as an
outcome could be based on microbiological endpoints
(pneumococcus or vaccine-serotype pneumococcus isolated
from spontaneous drainage or MEF isolates) or clinical end-
points (e.g., episodes, recurrence, or risk of tympanostomy-
tube placement). Clinical trials during the development
of these vaccines found that their eﬃcacies against a
microbiological outcome, vaccine-serotype pneumococcus
in MEF isolates, were quite similar (about 60%), yet vaccine
eﬃcacies against a clinical outcome, “clinical episodes” of
otitis media, varied considerably (values ranging from −1
to 34%) [2, 4, 9]. With respect to clinical endpoint, the
primary otitis media endpoint measured varied by study, as
did the otitis media deﬁnition. For the NCKP Vaccine Trial,
the primary outcome was number of episodes of or visits
for otitis media, obtained from computerized records using
diagnoses registered by emergency and pediatric physicians
in the NCKP populations; for the FinOM Vaccine Trial,
it was number of episodes of culture-conﬁrmed, vaccine-
serotype pneumococcal AOM (visibly abnormal tympanic
membrane suggesting middle-ear eﬀusion plus at least one
sign of acute infection) obtained by the clinical investigators
of the study; for the Native American Trial, it was visits with
clinicallydiagnosedepisodesofotitismedia,includingAOM,
asdocumentedbythepatients’treatingphysicians;forPOET
it was ﬁrst episode of vaccine-serotype pneumococcal AOM
(abnormal tympanic membrane or presence of MEF, plus
two predeﬁned clinical symptoms within 14 days preceding
the clinical diagnosis) conﬁrmed by an ear, nose, and throat
(ENT) specialist after referral by the patient’s pediatrician.
2.1. NCKP Vaccine Trial
2.1.1. NCKP Vaccine Trial Design and Methods. The NCKP
Vaccine Trial was conducted in 23 medical centers in
California,USA,from1995to1998.Childrenwererandomly
assigned to receive PCV7-CRM or control (meningococcal
serogroup C conjugate) vaccine, administered at ages 2, 4, 6,
and 12 to 15 months; they were followed until approximately
2 years of age and then until 3.5 years of age (long-term
follow-up, see 3.5.1., NCKP Vaccine Trial) [3, 15]. The study
enrolled a total of 37,868 children, 18,927 received 1 or
more doses of PCV7-CRM [15]. Otitis media was based on
diagnoses made by emergency physicians or pediatricians
in the NCKP-healthcare network [15]. A microbiological
endpoint was obtained from the 23 cases of spontaneously
draining ruptured tympanic membranes with culture of a
vaccine-serotype pneumococcus (intent-to-treat group, 17
fromchildreninthecontrolgroupand6fromchildreninthe
PCV7-CRM group; fully vaccinated group, 12 from children
in the control group and 4 from children in the PCV7-CRM
group).
2.1.2. NCKP Vaccine Trial Control Group. The study control
group included 18,942 children who received at least 1 dose
of control vaccine [3]. In the control group, there were
18,286 physician/clinic visits for otitis media among those
aged younger than 1 year, 21,721 visits among those aged 1
to 2 years, and 6446 visits among those aged older than 2
years [3]. Children aged younger than 1 year had a rate of
2.65 otitis media visits/year compared with 2.01 otitis media
visits/year for children aged 1 to 2 years and 1.18 otitis mediaInternational Journal of Otolaryngology 3
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visits/year for children aged older than 2 years [3]. The rate
of otitis media visits peaked at 10 months of age [3]. For
children aged 8 to 12 months, this translated to a rate of 22
to 24 visits per 100 children per month. For children aged 12
to 30 months, the rate was 11 to 12 visits per 100 children per
month [3].
2.1.3. NCKP Vaccine Trial Eﬃcacy Endpoints. The primary-
eﬃcacy endpoint of the NCKP Vaccine Trial was the eﬃcacy
of PCV7-CRM in preventing invasive pneumococcal disease
(IPD) due to the pneumococcal serotypes included in the
vaccine. Prevention of clinical episodes of otitis media (i.e.,
number of otitis media visits, including AOM visits) was a
secondary endpoint [15].
2.2. FinOM Vaccine Trial
2.2.1. FinOM Vaccine Trial Design and Methods. In the
FinOM study, eight clinics were set up in three Finnish cities
between 1995 and 1999 [2, 9]. Families in these cities were
informed of the study through various public media, and
parents interested in participating presented to the clinics
forenrollment.Healthyinfantsaged2monthsreceivedstudy
(PCV7-CRM or PCV7-OMPC) or control (hepatitis B virus)
vaccine as a 3-dose primary series at 2, 4, and 6 months
and a booster at 12 months [2]. (In FinOM, 55% of the
children born in the study area were enrolled.) Children who
were vaccinated with PCV7-OMPC received it on the same
schedule as PCV7-CRM, but with the following exception:
after 3 doses of PCV7-OMPC, about a ﬁfth of study vaccine
children(n = 187)received,astheﬁnal12-monthdose,a23-
valentpneumococcalpolysaccharidevaccine(Pneumovax23
[PPSV23]; Merck [West Point, PA, USA]) [9].
During the study period, parents were encouraged to
bring their children to a participating clinic if symptoms
of respiratory illness or AOM developed. Trained medical
staﬀ performed myringotomy with aspiration of MEF from
all children presenting with any clinical symptom suggest-
ing AOM to establish bacterial culture and pneumococcal
serotyping;MEFcultureswereobtainedduring93%ofAOM
clinic visits [2]. New episodes of AOM were deﬁned as those
occurring more than 30 days after a previous episode or
at any time after a previous episode if a diﬀerent serotype
or pathogen was identiﬁed [2]. The FinOM study design
followed all AOM episodes because, as the authors noted,
recurrent AOM is common [1, 5, 6]. In addition, all AOM
episodes were included in the analyses because selection of
a single event per child would likely have resulted, again as
noted, in biased population estimates due to the complicated
interdependence of recurrence and age [16]. Vaccine eﬃcacy
fromclinical and microbiological endpoints wasevaluated in
study children aged 6.5 to 24 months [2]. Most children who
participated in the FinOM study were included in the long-
term FinOM Trial Follow-up (see 3.5.2., FinOM Vaccine
Trial) [13].
2.2.2. FinOM Vaccine Trial Control Group. In the FinOM
control group, there were 1345 AOM episodes in 831
children [2, 9], and 587 (71%) children experienced 1 or
more documented AOM-related event(s) during the follow-
up period, with a range of 1 to 15 events per child
(median: 3 events) [2, 9, 16]. The overall incidence was
1.24 episodes of AOM PCPY [2]. Among the 1345 episodes,
MEF was obtained from 1267 episodes, of which 1082
were culture-conﬁrmed bacterial episodes [2]. The success
rate of obtaining a MEF sample was 97.2% when middle-
ear eﬀusion was suspected and an attempt was made to
collect MEF by myringotomy [2]. At least 1 MEF sample
was available from each of the 1819 AOM events (among
2595 ears of patients with AOM, as an episode could be
bilateral) [16]. S. pneumoniae, as the only pathogen or in
a mixed culture, represented 44% of all bacterial AOM in
the control group (age range: 2 to 24 months [16]); 60% of
pneumococcal AOM was caused by serotypes included in the
vaccineand20%wascausedbyvaccine-relatedserotypes[2].
2.2.3. FinOM Vaccine Trial Eﬃcacy Endpoints. The primary-
eﬃcacy endpoint of the FinOM Vaccine Trial was the total
number of episodes of AOM due to vaccine serotypes [2].
Upon examination by the clinic physician, AOM in FinOM
was deﬁned as the abnormal appearance of the tympanic
membrane suggesting eﬀusion, plus a single feature of acute
clinical illness such as fever, earache, diarrhea, or signs
of respiratory infection [2]. Secondary-eﬃcacy endpoints
included vaccine eﬃcacy in preventing ﬁrst and subsequent
episodes of AOM, and eﬃcacy against recurrent AOM [2].
2.3. Native American Trial
2.3.1. Native American Trial Design and Methods. Ad o u b l e -
blind, community-randomized clinical trial conducted
among Navajo and White Mountain Apache children from
April 1997 to August 2000 compared the eﬃcacy of PCV7-
CRM for pneumococcal disease against a control (meningo-
c o c c a lg r o u pCc o n j u g a t e )v a c c i n e[ 12, 17]. Infants were
scheduled to receive 3 doses of vaccine at 2, 4, and 6 months
ofage,followedbyaboosteradministeredat12to15months
of age [10]. This study used community randomization;
8292 children were enrolled, selected from 38 geographically
deﬁned, residence-based randomization units that were
clusters of existing, well-deﬁned communities, and 8045
of these children were included in the group-randomized
design of this eﬃcacy trial and received vaccine (PCV7-CRM
=4142;control=3903)[10,13,17].Attrialcompletion,4476
children were eligible for a retrospective chart review based
on having been aged less than 7 months when they received
the ﬁrst dose of vaccine, having received 3 doses of study
vaccine by age 12 months, and having had a minimum of 30
days between doses [12]. From this group of 4476 children, a
sample of 1000 charts was considered necessary to provide
statistical power; charts from 944 children were chosen
randomly [12]. Researchers evaluated “clinically diagnosed
episodes of otitis media (all types of otitis media diagnosis)”
occurring in study children until they reached age 2 years
[12]. The primary eﬃcacy subgroup (n = 856) met the
chart-reviewcriteria(PCV7-CRM = 424;control = 432);the
per-protocol subgroup (n = 803) was ﬁrst vaccinated on or
after 42 days of age, third dose was received before 365 days6 International Journal of Otolaryngology
of age, booster dose was received between 365 and 480 days
of age, and there was at least a 60-day interval between the
end of the primary and the booster dose. Eﬃcacy in the per-
protocol group was measured from 14 days after completion
of the third dose, while it began immediately after the ﬁrst
dose in the primary eﬃcacy group. As a microbiological
endpoint, there were 51 spontaneously draining otitis media
episodes that grew S. pneumoniae from the eﬃcacy trial
population (n = 8292). From the 51 spontaneously draining
otitis media episodes that grew S. pneumoniae,s e r o t y p ed a t a
was obtained from 23 isolates collected for serotyping (11
PCV7serotypesand12non-PCV7serotypes);onlythePCV7
serotype results are available [12].
2.3.2. Native American Trial Control Group. In the primary
eﬃcacy subgroup of children who met chart-review criteria
(n = 856), there was a high burden of disease; in the per-
protocol subgroup of children who met criteria for age-
appropriate vaccination (n = 803), there were 736 episodes
of AOM (816 otitis media episodes) in the control group
(n = 432), an incidence of 1.4 episodes PCPY: for all otitis
media of 1.5 episodes PCPY, and for AOM of 1.3 episodes
PCPY [12].
2.3.3. Native American Trial Eﬃcacy Endpoints. The end-
points of the Native American Trial included eﬃcacy of
PCV7-CRM in preventing IPD, as well as indirect eﬀects
of the vaccine in a community through reduction in
carriage and secondary attack rates due to the pneumococcal
serotypes included in the vaccine [10]. The primary eﬃcacy
endpoint used in the subanalysis that evaluated PCV7-CRM
otitis media eﬃcacy was prevention of clinically diagnosed
episodes of otitis media, including AOM [12].
2.4. POET
2.4.1. POET Design and Methods. POET was conducted in
pediatric centers in the Czech Republic and Slovakia from
2000 to 2004, and healthy infants aged approximately 3
months received 4 doses (a 3-dose primary series at 3, 4, and
5 months plus a booster at 12 to 15 months) with PCV11-
PD or control (hepatitis A virus) vaccine [4]. (In regions
participating in POET, up to 20% of the infant population
was enrolled [18].) Parents of these infants would bring their
sick children to local pediatricians, who referred children
with suspected AOM to ENT specialists who also were
participating in the study. The ENT specialist performed
tympanocentesis for bacterial culture and serotyping after
conﬁrming the local pediatrician’s diagnosis [4]. Follow-up
for the per-protocol group started 2 weeks after the third
vaccine dose and continued until the age of 24 to 27 months
[4]. New episodes of AOM were deﬁned as those occurring
m o r et h a n3 0d a y sa f t e rap r e v i o u se p i s o d eo ra ta n yt i m e
after a previous episode if a diﬀerent serotype or pathogen
was identiﬁed [4]. This trial focused on microbiological
endpoints in the ﬁrst two years of life, and no long-term
follow-up of study participants was conducted.
2.4.2. POET Control Group. In the POET control group, 499
clinical episodes of AOM (i.e., specialist-referral episodes)
were recorded in 2452 children who completed the study
per-protocol. Of these clinical episodes, 61% (306/499)
were culture-conﬁrmed bacterial episodes [4]. Of the
306 conﬁrmed bacterial episodes, 62% (189/306) were
culture-conﬁrmed pneumococcal episodes; 75% (141/189)
of culture-conﬁrmed pneumococcal episodes were caused
by serotypes included in the vaccine, and 12% (23/189)
were caused by vaccine-related serotypes [4]. The overall
incidenceofAOMwas0.12episodesofAOMPCPY(i.e.,12.5
episodes per 100 person-years of follow-up) [4].
2.4.3. POET Eﬃcacy Endpoints. In POET, the primary end-
point was eﬃcacy against the ﬁrst episode of AOM due to
vaccine pneumococcal serotypes [4]. Upon examination by
a pediatrician and then an ENT specialist, AOM in POET
was based upon an abnormal tympanic membrane or the
presence of MEF, plus two predeﬁned clinical symptoms
within14daysprecedingthediagnosis. Themainsecondary-
eﬃcacy endpoint of POET was eﬃcacy against the ﬁrst
episode of AOM caused by nontypable H. inﬂuenzae [4].
3. Results
TheclinicaltrialresultsaresummarizedinTables2-6[2–4,7,
9,12,13,15].Per-protocolandintent-to-treateﬃcacyvalues,
where available, are reported in Table 2 (e.g., otitis media
episodes, recurrent otitis media, spontaneous perforation,
and risk of tympanostomy-tube placement) [2–4, 9, 12,
15]. The number of microbiological isolates due to vaccine
serotypes in the control group or the pneumococcal vaccine
group is presented in Table 3 [2, 4, 9, 12]. In the long-term
follow-up (PCV7-CRM/NCKP and PCV7-CRM/FinOM),
vaccine per-protocol eﬃcacy against clinical endpoints (e.g.,
visits or episodes, recurrence, tympanostomy-tube place-
ment, AOM-related ambulatory visits, or rate of antibiotic
prescriptions for AOM), and intent-to-treat values where
available, are in Table 4 [3, 7, 13]. The vaccine-attributable
reduction values (otitis media episodes, bacteria in MEF iso-
lates, pneumococcus in MEF isolates, and vaccine-serotype
pneumococcus in MEF isolates), as calculated, are reported
in Table 5 [2, 4, 9, 12]. The vaccine eﬃcacy and vaccine-
attributablereductionvalues(i.e.,numberofcasesprevented
per100childrenvaccinated),byclinicaltrial,arepresentedin
Table 6 [2, 4, 9, 12].
3.1. NCKP Vaccine Trial. The PCV7-CRM group included
18,927 children who received at least 1 dose of PCV7-CRM
[15]. In this study, eﬃcacy against vaccine serotypes was
66.7% in the per-protocol analysis of the subsample cultured
after spontaneous rupture (Tables 2 and 3)[ 15]. Vaccine
eﬃcacy in preventing the number of otitis media visits,
including AOM visits, was 7.0% (95% conﬁdence interval
[CI] = 4.1–9.7) in the per-protocol analysis [3, 15]. Other
eﬃcacy results are shown in Table 2 [3, 15].International Journal of Otolaryngology 7
Table 2: Vaccine eﬃcacy values in the PCV clinical trials with otitis media as an endpoint [2–4, 9, 12, 15] .A d a p t e dw i t hp e r m i s s i o nf r o m
Fletcher and Fritzell, 2007 Elsevier Ltd. All rights reserved [7].
NCKP [3, 15] FinOM [2] FinOM [9] Native American
Trial [12] POET [4]
Study vaccine PCV7-CRM PCV7-CRM PCV7-OMPC PCV7-CRM PCV11-PD
Period 1995–1998 1995–1999 1995–1999 1997–2000 2000–2004
Country USA Finland Finland USA Czech Republic,
Slovakia
No. of children 37,868 1662 1666 856 4907
Age 2–24 months 2–24 months 2–24 months 6w e e k st o
24 months
6w e e k st o
24–27 months
Clinical endpoints∗: vaccine eﬃcacy, % (95% CI)
Otitis media episodes 7 (4–10) 6 (−4 to 16) −1( −12 to 10) 0( −19 to 16)
−3( −21 to 12)∗∗ 34 (21–45)
Recurrent otitis media†
3/4 9 (3–15) 16 (−6 to 35) — 5( −52 to 41)
14 (−34 to 44)∗∗ 56 (−2 to 81)
4/5 12 (2–21) — — — —
5/6 23 (7–36) — — — —
Spontaneous perforation — 23 (−18 to 50) — — —
Risk of ﬁrst tympanostomy-tube placement 20 (2–35) 4 (−19 to 23) — 28 (−225 to 84)
22 (−256 to 83)∗∗ 60 (−27 to 88)
S. pneumoniae microbiological endpoints∗: vaccine eﬃcacy, % (95% CI)
All serotypes — 34 (21–45) 25 (11–37) — 52 (37–63)
Vaccine serotypes PP 67 (—) 57 (44–67)
56 (44–66)
60 (43–72)‡
65 (34–81)§
64 (−34 to 90) 58 (41–69)
ITT 65 (—) 54 (41–64) — — 53 (35–66)
Cross-reactive serotypes — 51 (27–67)
−5( −47 to 25)
−21 (−98 to 17)‡
−25 (−88 to 49)§
— 66 (22–88)
Any other serotypes — −33 (−80 to 1)
−27 (−70 to 6)
−22 (−86 to 19)‡
−146 (−405 to 20)§
—8 ( −64 to 49)
∗See Table 1 for primary otitis media endpoint, otitis media deﬁnition, myringotomy criteria, and source of MEF in each study.
∗∗Primary eﬃcacy group (see Section 2.3.1. Native American Trial Design and Methods).
†Number of episodes in 6 months/number of episodes in 1 year.
‡Among children who received PCV7-OMPC booster, during a follow-up period lasting from 12 to 24 months.
§ Among children who received a ﬁnal 12-month dose of 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23 [PPSV23], Merck [West Point, PA,
USA]) [9], during a follow-up period lasting from 12 to 24 months.
Reported values are rounded to whole numbers; dash line indicates not reported.
CI: conﬁdence interval; ITT: intent to treat; PP: per-protocol.
3.2. FinOM Vaccine Trial
3.2.1. PCV7-CRM. In the FinOM PCV7-CRM group, 1251
episodes of AOM were diagnosed among 831 vaccinated
children during the 18-month follow-up period [2]. Among
the 1251 episodes, 1177 were conﬁrmed by the presence of
MEF,ofwhich965wereculture-conﬁrmedbacterialepisodes
(Table 5)[ 2]. Eﬃcacy in preventing total number of episodes
of pneumococcal AOM due to vaccine serotypes (obtained
bymyringotomy),theprimaryendpoint,was57%(95%CI=
44–67) in the per-protocol analysis (Tables 2 and 3)[ 2]. The
overall incidence of AOM was 1.16 episodes PCPY (versus
1.24 in the control group), for a vaccine eﬃcacy against the
number of episodes of AOM (ﬁrst and subsequent episodes)
of 6% (95% CI =− 4t o1 6 )[ 2]. Other eﬃcacy results are
shown in Table 2 [2].
3.2.2. PCV7-OMPC. In the PCV7-OMPC arm of FinOM,
1364 episodes of AOM were diagnosed in 835 vaccinated
children,ofwhich1279wereconﬁrmedthroughthepresence
of MEF, with 1073 culture-conﬁrmed bacterial episodes
(Table 5)[ 9]. As described earlier (see Section 2.2.1), some
of the children in the PCV7-OPMC study arm received a8 International Journal of Otolaryngology
Table 3: Case split (control group : pneumococcal vaccine group) for S. pneumoniae serotypes in the PCV clinical trials with otitis media as
an endpoint [2, 4, 9, 12].
Case split (control vaccine group : pneumococcal vaccine group)
FinOM [2] FinOM [9] Native American Trial [12]∗ POET [4]
Study vaccine PCV7-CRM PCV7-OMPC PCV7-CRM PCV11-PD
Serotype
1— — — 1 : 1
3 13:13 13:11 — 17:20
4 4:2 4:1 2:0 3:0
5— — — 0 : 0
6B 56:9 56:12 0:0 24:3
7F — — — 1:0
9V 11:5 11:2 0:0 8:3
14 26:8 26:11 1:0 22:1
18C 17:7 17:8 2:0 5:3
19F 58:43 58:37 3:3 43:24
23F 82:33 82:40 0:0 18:5
∗Data obtained from 23 isolates collected for serotyping (11 PCV7 serotypes and 12 non-PCV7 serotypes) from 51 spontaneously draining otitis media
episodes that grew S. pneumoniae; only the PCV7 serotype results are available.
For PCV7-CRM/NCKP, there were 16 cases of spontaneously draining ruptured tympanic membranes with culture of a vaccine-serotype pneumococcus in
the fully vaccinated group (i.e., child <16 months of age who received three or more doses of vaccine, and child ≥16 months old who had received four doses
of vaccine), 12 from children in the control group, and 4 from children in the PCV7-CRM group children. Four cases in fully PCV7-CRM-vaccinated children
were serotype 19F; distribution of vaccine-serotype isolates in the control group was not reported [3, 15].
Dash line indicates not reported.
PPSV23 vaccine as the ﬁnal dose at 12 months after receiving
3 primary series doses of PCV7-OMPC at 2, 4, and 6 months
of age [9]. PCV7-OMPC eﬃcacy in preventing AOM due to
vaccine serotypes (obtained by myringotomy), the primary
endpoint, in the per-protocol analysis was 56% (95% CI =
44–66) (Tables 2 and 3)[ 9]. Vaccine eﬃcacy in preventing
all episodes of AOM was –1% (95% CI=− 12 to 10) [9].
When these groups were split out, the overall incidence
of AOM caused by vaccine serotypes was 7.55 episodes
per 100 person-years among children who received 4 doses
of PCV7-OMPC and 7.66 episodes per 100 person-years
among children who received 3 doses of PCV7-OMPC plus a
PPSV23 ﬁnal dose [9]. Vaccine eﬃcacy against AOM due to
vaccine serotypes in the per-protocol groups was 60% (95%
CI = 43–72) in the 4-dose PCV7-OMPC group (n = 631)
and 65% (95% CI = 34–81) in the PPSV23 ﬁnal dose group
(n = 187) (Table 2)[ 9].
3.3. Native American Trial. Of the 856 children in the
primary-eﬃcacyanalysis,424hadreceivedPCV7-CRM[13].
The PCV7-CRM-vaccinated children had a total of 1092
AOM episodes during the study period, giving an incidence
of 1.4 AOM episodes PCPY (Table 1)[ 12]. In the per-
protocol analysis, there were 706 AOM episodes (785 otitis
media episodes) in the PCV7-CRM group (Table 5). Vaccine
eﬃcacy was 64% (95% CI =− 34 to 90) against otitis media
due to vaccine serotypes, as measured in a subgroup of 23
isolates from spontaneously draining otitis media episodes
that had been collected for serotyping (Tables 2 and 3)[ 12].
Vaccine eﬃcacy against clinically diagnosed episodes of otitis
media,includingAOM(i.e.,“otitismedia,acuteotitismedia,
bilateral otitis media, chronic otitis media, otitis media with
perforation, otorrhea, pressure-equalizing tube placement,
perforated tympanic membrane, serous otitis media, and
bullous myringitis”) was 0% (95% CI =− 19 to 16) [12].
Other available eﬃcacy results are shown in Table 2 [12].
3.4. POET. In the PCV11-PD group, 333 clinical episodes of
ENT-referred AOM were diagnosed in 2455 children who
were vaccinated, of which 322 were episodes with MEF
obtained by aspiration, and 178 were culture-conﬁrmed bac-
terial episodes [4]. Of the 178 conﬁrmed bacterial episodes,
92 were culture-conﬁrmed pneumococcal episodes (Table 5)
[4]. PCV11-PD vaccine eﬃcacy against ﬁrst occurrence of
AOM due to vaccine serotypes in the per-protocol analysis,
the primary endpoint, was 52.6% (95% CI = 35.0 to 65.5)
(Tables 2 and 3)[ 4]. PCV11-PD vaccine eﬃcacy against ﬁrst
occurrence of AOM due to nontypable H. inﬂuenzae (NTHi)
was 31.1% (95% CI =− 3.7 to 54.2), the main secondary
endpoint [4].
Vaccine eﬃcacy against any episode of ENT-referred
AOM during per-protocol follow-up was 34% (95% CI = 21
to45)[4].(TheoverallincidenceofAOMwas0.083episodesInternational Journal of Otolaryngology 9
Table 4: Vaccine eﬃcacy values in the long-term follow-up of PCV clinical trials with otitis media as an endpoint [3, 13]. Adapted with
permission from Fletcher and Fritzell, 2007 Elsevier Ltd. All rights reserved [7].
Follow-up clinical trials
NCKP [3] FinOM [13]
Study vaccine PCV7-CRM PCV7-CRM
Period 1998–1999 1999–2001
No. of children 27,754 756
Age Until aged 3.5 years Until aged 4–5 years
Clinical endpoints∗: vaccine eﬃcacy, % (95% CI)
Otitis media visits (NCKP) or episodes (FinOM) PP 8 (5–11) 8 (−2 to 16)
ITT 7 (5–9) —
Recurrent otitis media∗∗
3/4 10 (7–13) 18 (1–32)
5/6 — 50 (15–71)†
≥10‡ 26 (12–38) —
All tympanostomy-tube placements 23 (−10 to 46) 39 (4–61)†,§
44 (19–62)†,¶
Rate of AOM-related ambulatory visits 8 (5–10) —
Rate of antibiotic prescriptions for AOM 6 (4–7) —
∗See Table 1 for primary otitis media endpoint, otitis media deﬁnition, myringotomy criteria, and source of MEF in each study.
∗∗Number of episodes in 6 months/number of episodes in 1 year.
†In children diagnosed with “chronic otitis media with eﬀusion.”
‡Eﬃcacy against 10 or more episodes within 6 months.
§ Primary analysis set (see Section 3.5.2. FinOM Vaccine Trial).
¶ Secondary analysis set (see Section 3.5.2. FinOM Vaccine Trial).
Reported values are rounded to whole numbers; dash line indicates not reported.
CI: conﬁdence interval; ITT: intent to treat; PP: per-protocol.
PCPYinthevaccinegroupversus0.125AOMepisodesPCPY
inthecontrolgroup[4].)Vaccineeﬃcacyagainstallepisodes
of clinical AOM (ENT-referred and episodes that were not
referred to an ENT) was apparently not reported.
3.5. Trial Results: Long-Term Follow-up. Long-term follow-
up information is available from the PCV7-CRM/NCKP and
the PCV7-CRM/FinOM clinical trials and is summarized in
Table 4. Where available, results for per-protocol and intent-
to-treat analyses are given in the table.
3.5.1. NCKP Vaccine Trial. The follow-up to the NCKP Vac-
cine Trial, conducted from 1998 to 1999, looked speciﬁcally
at otitis media endpoints (e.g., overall incidence, risk of
frequent otitis media, or use of tympanostomy tubes) in
children aged 3.5 years or younger [3]. Children received a
4-dose schedule (2, 4, 6, and 12 to 15 months), with per-
protocol analysis beginning 14 days after completion of the
primary series. PCV7-CRM reduced otitis media visits by
7.8% (95% CI = 5.4–10.2) (Table 4)[ 3]. The reductions in
otitis media visits in the PCV7-CRM group versus control,
based on age, were 8.2% (95% CI = 5.1–11.1) for children
younger than 1 year, 8.7% (95% CI = 5.8–11.6) for children
aged 1 to 2 years, and 3.7% (95% CI = −1 . 8t o8 . 8 )f o r
children older than 2 years [3].
3.5.2. FinOM Vaccine Trial. In the FinOM Trial Follow-
up, families of children who had been monitored until the
age of 24 months in FinOM and who were still living in
the area were contacted and invited to a follow-up visit
when the children were aged 4 to 5 years (Table 4)[ 13].
The primary analysis population comprised 756 children
(403 from the PCV7-CRM group and 353 from the control
group)[13]. Information on tympanostomy-tube placement
for the primary analysis was obtained through collective
review from medical centers of private patient records from
children in FinOM (up to age 24 months), parent interviews
at the follow-up visit, and district hospital records [13]. A
secondary analysis included 1490 children and used data
from hospital records up to June 2001 in the study area
[13]. Per-protocol vaccine eﬃcacy for all tympanostomy-
tube placement was 39% (95% CI = 4–61) in the primary-
analysis population and 44% (95% CI = 19–62) in the
secondary-analysis population (Table 4)[ 13].
4. Discussion and Conclusions
These clinical trials demonstrate that AOM is a vaccine-
preventable disease; the impact of PCVs on microbiological
endpoints (pneumococcus or vaccine-serotype pneumococ-
cus), clinical endpoints, or both has been documented in ﬁve
studies that diﬀered in many respects, for example, primary10 International Journal of Otolaryngology
Table 5: Vaccine-attributable reduction values based on otitis media episodes and MEF isolates (bacteria, pneumococcus, or vaccine-
serotype pneumococcus) from the PCV clinical trials with otitis media as an endpoint (PP groups) [2, 4, 9, 12].
Otitis media endpoint
No. of cases (no. vaccinated)
Diﬀerence∗ Vaccine-attributable reduction†
Vaccine group Control group
Otitis media episodes
PCV7-CRM/FinOM 1251 (786) 1345 (794) −94 12
PCV7-OMPC/FinOM 1364 (805) 1345 (794) +19 NA
PCV7-CRM/Native American 785 (424) 816 (432) −31 7
PCV11-PD/POET 333 (2455) 499 (2452) −166 7
Bacteria in MEF isolates‡
PCV7-CRM/FinOM 965 (786) 1082 (794) −117 15
PCV7-OMPC/FinOM 1073 (805) 1082 (794) −91
PCV7-CRM/Native American — — — —
PCV11-PD/POET 178 (2455) 306 (2452) −128 5
Pneumococcus in MEF isolates
PCV7-CRM/FinOM 271 (786) 414 (794) −143 18
PCV7-OMPC/FinOM 314 (805) 414 (794) −100 12
PCV7-CRM/Native American — — — —
PCV11-PD/POET 92 (2455) 189 (2452) −97 4
Vaccine-serotype pneumococcus in
MEF isolates
PCV7-CRM/FinOM 107 (786) 250 (794) −143 18
PCV7-OMPC/FinOM 110 (805) 250 (794) −140 17
PCV7-CRM/Native American 3 (424) 8 (432) −51
PCV11-PD/POET 60 (2455) 141 (2452) −81 3
∗Vaccine group minus control group.
†Vaccine-attributable reduction: no. of cases prevented per 100 children vaccinated, which is the diﬀerence (vaccine group minus control group) divided by
the no. vaccinated, then normalized per 100 children vaccinated.
‡S. pneumoniae, H. inﬂuenzae,a n dM. catarrhalis, or any combination of these.
Dash line indicates not reported.
NA: not applicable. PP: per-protocol.
endpoint measured, age at follow-up, source of MEF for
culture, case ascertainment, and type of randomization [2–
4, 12, 15]. The primary endpoint diﬀered between PCV11-
PD/POET, deﬁned as the ﬁrst episode of AOM [4], and the
other 4 studies, where all episodes or all visits for AOM were
used[2,3,10,12,15].Theageatfollow-updiﬀeredaswell.In
PCV7-OMPC/FinOM, PCV7-CRM/Native American Trial,
and PCV11-PD/POET, children were followed until the
second year of life [3, 4, 9, 10, 12], whereas children from
PCV7-CRM/NCKP and PCV7-CRM/FinOM were followed,
respectively, until the age of 3.5 years or until 4 to 5
years [13]. Investigators in PCV7-CRM/FinOM, PCV7-
OMPC/FinOM, and PCV11-PD/POET obtained MEF by
myringotomy with aspiration from children presenting with
the otitis media endpoint who matched the myringotomy
criteria [2, 4, 9]. For PCV7-CRM/FinOM, this included all
children presenting with AOM; for PCV7-OMPC/FinOM,
this involved all children presenting with respiratory infec-
tion or symptoms suggesting AOM if AOM was diagnosed
at the visit; for PCV11-PD/POET, pediatricians decided
whether to refer children with AOM clinical features to an
ENT specialist for conﬁrmation and myringotomy (Table 1).
By contrast, MEF was obtained only from cases with
spontaneous rupture in the PCV7-CRM/NCKP and PCV7-
CRM/Native American trials [3, 10, 12]. Case ascertainment
included all otitis media events for 4 of the trials (PCV7-
CRM/NCKP, PCV7-CRM/FinOM, PCV7-OMPC/FinOM,
and PCV7-CRM/Native American) [2, 3, 9, 10, 12]. In
PCV11-PD/POET, ENT referral was not systematic and may
have been reserved for more severe cases. Subsequent to
publication of the results, the PCV11-PD/POET principal
investigator noted that POET was not designed to capture
every AOM episode, but only the most “disturbing” cases
that led to ENT referral [1]. A recent meta-analysis of
conjugate-vaccine trials noted that vaccines have a greater
impact on the most severe forms of AOM [19]. In a
reanalysis of the PCV7-CRM/FinOM dataset that applied
PCV11-PD/POET case deﬁnitions, the eﬃcacy of PCV7-
CRMagainstclinicalAOMoragainstvaccine-serotypepneu-
mococcal AOM was not aﬀected signiﬁcantly by diﬀerencesInternational Journal of Otolaryngology 11
in case deﬁnitions. In emphasizing the completeness of
case ascertainment in PCV7-CRM/FinOM, the authors of
the reanalysis concluded that the reported diﬀerences in
vaccine-eﬃcacy values between trials were due to results
of several factors, including diﬀerences in study method-
ology, particularly case detection, as well as variations
in the epidemiology of pneumococcal or serotype-speciﬁc
pneumococcal AOM, or the eﬀect of PCV11-PD against
NTHi [20]. Finally, four of the studies (PCV7-CRM/NCKP,
PCV7-CRM/FinOM, PCV7-OMPC/FinOM, and PCV11-
PD/POET) used individual randomization whereas the
PCV7-CRM/Native American Trial used community-based
randomization.
For the microbiological endpoint, the vaccine eﬃcacy
against pneumococcal vaccine serotype otitis media was
similar across the following trials: 67%, PCV7-CRM/NCKP;
57%, PCV7-CRM/FinOM; 64%, PCV7-CRM/Native Amer-
ican Trial; 56%, PCV7-OMPC/FinOM; 58%, PCV11-
PD/POET (Tables 2 and 3)[ 2–4, 12, 15]. By contrast,
the values for the clinical endpoints varied between trials.
Against all clinical episodes, vaccine eﬃcacy was 7% (PCV7-
CRM/NCKP), 6% (PCV7-CRM/FinOM), −1% (PCV7-
OMPC/FinOM), and −0.4% (PCV7-CRM/Native Amer-
ican Trial); it was 34% against ﬁrst episodes of ENT
specialist-referralcases(PCV11-PD/POET).Bothforfollow-
up through 2 years of age for the ﬁve trials, and in long-
term follow-up for two of the trials (PCV7-CRM/NCKP,
until 3.5 years of age; PCV7-CRM/FinOM, until 4–5 years of
age),largervaluesforvaccineeﬃcacyinpreventingrecurrent
AOM and reducing the need for tympanostomy tubes were
demonstrated,suggestingthatpreventionofearlyepisodesof
AOM through vaccination may prevent subsequent episodes
of complicated otitis media [3].
An intriguing ﬁnding was the lack of vaccine eﬃcacy
against clinically diagnosed episodes of otitis media, includ-
ing AOM, in the PCV7-CRM/Native American Trial, while
the vaccine-attributable reduction against otitis media in
the PCV7-CRM/Native American Trial was 7 cases avoided
per 100 children vaccinated, which is the same as the
value demonstrated for PCV11-PD/POET but less than the
value for PCV7-CRM/FinOM (12 cases avoided per 100
children vaccinated) (Table 5). Furthermore, PCV7-CRM
showed good eﬃcacy otherwise against the microbiologi-
cal endpoint, pneumococcal vaccine serotype otitis media,
comparable to each of the other four clinical trials (Table 2)
[10, 12]. This lack of vaccine eﬃcacy against clinically
diagnosed episodes of otitis media may have been due
to a lower proportion of vaccine serotypes in the study
population, where only about half of all IPD was caused
by vaccine serotypes, which is a low proportion of vaccine
serotype IPD compared with other populations [10, 12].
In the AOM subgroup, vaccine serotypes were present in
11 cultures (8 in the control group and 3 in the PCV7-
CRM group) from 23 cultures overall of MEF obtained from
spontaneously draining cases, which is consistent with the
IPD ﬁndings, but because systematic MEF cultures were
not performed, this remains speculation [12]. The lack of
vaccine eﬃcacy demonstrated against clinical otitis media
also could be related to the use of community, rather than
individual, randomization. This suggests that, interfering
with transmission, the basis of the “herd” eﬀect that has
been associated with PCV7-CRM vaccine, may play an
important role in vaccine eﬃcacy against all-cause otitis
media [17]. There also was no clinical eﬃcacy demonstrated
in the PCV7-OMPC/FinOM trial, which used individual,
randomization, although it is not possible to diﬀerentiate the
impact on any AOM between children who received 4 doses
of PCV7-OMPC and those who received 3 doses of PCV7-
OMPC plus a PPSV23 ﬁnal dose because separate vaccine
eﬃcacy calculations were not provided.
In addition to the diﬀerences in methodology, the studies
also diﬀered in the characteristics of the rate of otitis
media reported from the control group, the underlying
prevalence of S. pneumoniae AOM in the control group,
and the proportion of vaccine-type AOM episodes in the
control group. The overall incidence of AOM in the PCV11-
PD/POET control group was low, approximately a tenth
that is observed in FinOM and other studies [20]. Whether
this was due to the POET study design, which may not
have reﬂected the full burden of AOM, or factors unique
to the location or time of the study were involved (e.g.,
antibiotic use, family size, or daycare-center population) is
unclear. The authors of a reanalysis of the FinOM dataset
that applied POET case deﬁnitions highlighted that [20]
“The AOM episodes captured may have been a subgroup of
the total number of cases.” The incidence of AOM PCPY
in the control groups of PCV7-CRM/NCKP (2.0 to 2.6)
and the PCV7-CRM/Native American (1.4) trials are more
consistent with the FinOM control group (1.24) than the
PCV11-PD/POET control group (0.12) (Table 1)[ 2, 3, 7,
10, 12, 15]. A diﬀerence in the underlying prevalence of S.
pneumoniae AOM in the control groups of FinOM (38%
of positive cultures) and POET (62% of positive cultures)
may be relevant to the observed diﬀerence in vaccine eﬃcacy
against episodes of otitis media [19]. The proportion of
vaccine-serotype AOM episodes was higher in the PCV11-
PD/POET study (28% of clinical AOM episodes in the POET
study control group compared with 19% in the FinOM study
control group), which may be due to true epidemiologic
diﬀerences or may reﬂect diﬀerences in case detection [20].
InthePCV7-CRM/NCKPandPCV7-CRM/NativeAmerican
trials, by contrast, microbiological samples were obtained
only after spontaneous rupture. Microbiological ﬁndings
from these 2 studies cannot help cast any light on the
issue because they present the number of vaccine-serotype
pneumococcus only, distributed between the PCV7-CRM
and the control group.
Based on the vaccine-attributable reductions docu-
mented during both FinOM trials, the PCV7-CRM/Native
American Trial, and the PCV11-PD/POET, the predicted
impact of a national immunization program with these
vaccines on otitis media episodes, bacteria in MEF isolates,
pneumococcus in MEF isolates, and vaccine-serotype pneu-
mococcus in MEF isolates can be estimated (Tables 5 and 6).
The PCV7-CRM/FinOM trial can provide a good basis for
estimating the potential impact of pneumococcal vaccina-
tion. Adherence throughout the study was high (95%), rates
of AOM in FinOM were consistent with those reported in12 International Journal of Otolaryngology
Table 6: Vaccine eﬃcacy and vaccine-attributable reduction values in the PCV clinical trials with otitis media as an endpoint [2, 4, 9, 12].
PCV7-CRM/FinOM [2] Otitis media episodes Bacteria∗ Sp Vaccine serotype
Vaccine eﬃcacy 7% — 34% 57%
Vaccine-attributable reduction† 12per100 17per100 18per100 18 per100
PCV7-OMPC/FinOM [9] Otitis media episodes Bacteria∗ Sp Vaccine serotype
Vaccine eﬃcacy −1% — 25% 56%
Vaccine-attributable reduction† — 1per 100 12 per 100 17per100
PCV7-CRM/Native American
Trial [12]
Otitis media episodes Bacteria∗ Sp Vaccine serotype
Vaccine eﬃcacy −0.1% — — 64%
Vaccine-attributable reduction† 7per100 — — 1per100
PCV11-PD/POET [4] Outpatient
visit episodes
Specialist
referral
episodes
Bacteria∗ Sp Vaccine serotype
Vaccine eﬃcacy — 32% 42% 52% 58%
Vaccine-attributable reduction† — 7per100 5per100 4per100 3per100
∗Culture-conﬁrmed S. pneumoniae, H. inﬂuenzae, M. catarrhalis, or any combination of these.
†Vaccine-attributable reduction: no. of cases prevented per 100 children vaccinated, which is the diﬀerence (vaccine group minus control group) divided by
the no. vaccinated, then normalized per 100 children vaccinated (see Table 5 for calculations).
Dash line indicates not reported.
Bacteria: bacteria in MEF isolates; Sp: pneumococcus in MEF isolates; vaccine serotype: vaccine-serotype pneumococcus in MEF isolates.
most other studies, and nearly all (93%) AOM cases were
conﬁrmed through myringotomy [2, 20]. During a 1.5-year
period(December1995toApril1997),morethanhalf(55%)
ofthechildrenborninthestudyareawereenrolled,andthese
children were followed until the age of 24 months. Based on
this double-blind, randomized, controlled design, intended
to measure the direct eﬀect of the vaccine [2], the anticipated
impact of vaccination with PCV7-CRM is prevention of
approximately 12 AOM visits per year for every 100 children
younger than 2 years of age who are vaccinated (Tables 5
and 6). This has been realized in numerous surveillance
studies in the USA, where between 23 and 25 AOM visits
per year were prevented for every 100 children (less than 2
y e a r so fa g e )v a c c i n a t e d[ 21, 22] (e.g., using data reported by
Zhou et al. [21], it can be calculated that 929 visits per 1000
person-years were prevented during the period 2001 to 2004;
divided by 4 years, this yields 232.5 visits per 1000 person-
years prevented annually, or 23 visits avoided per year per
100 children vaccinated). The reduction in nasopharyngeal
carriage of vaccine-serotype pneumococci among vaccinated
infants and the consequential reduction in transmission
[23] established from a PCV7-CRM national immunization
program [22] may account, at least in part, for the fact that
postlicensure surveillance endpoint values are even greater
than could have been anticipated from FinOM. PCV7 uptake
nationwide was approximately 41% in 2002, 68% in 2003,
and 73% in 2004, when the US study was conducted [24].
Other possible factors on the impact of PCV7-CRM in the
US national immunization program include the long-term
positive impact on subsequent episodes of AOM resulting
from the prevention of an initial case of pneumococcal otitis
media in a young child [16], as well as any changes in the
management of otitis media that may have happened since
the widespread introduction of PCV7-CRM, variations in
the severity of seasonal inﬂuenza, or enhanced uptake of
trivalent-inactivated inﬂuenza vaccine among infants [21,
25, 26].
ClinicalexperiencewithPCV7-CRMsinceitswidespread
adoption following initial licensure in 2000 demonstrates
reduced rates of all clinical episodes of AOM and reduced
rates of AOM-related outpatient visits and hospitalizations.
Changes in the burden of otitis media after availability
of PCV7-CRM vaccination include 36.4% vaccine eﬃcacy
againsthospitalizationforAOMinItaly(regionalimmuniza-
tion program, 2+1 schedule) [27], 38% reduction in rates of
otorrhea per emergency department visit in Greece (national
immunization program, 3 + 1 schedule) [28], a 36% reduc-
tion in emergency visits due to suspected AOM in children
at risk for recurrent AOM (rAOM) in Sweden (randomized,
controlled trial, 3 + 1 schedule) [29], and, as noted, a
42.7% reduction in the rate of ambulatory visits attributable
to AOM in USA (national immunization program, 3 + 1
schedule) [21]. In PCV11-PD/POET, vaccine eﬃcacy against
ﬁrst-episode, ENT-referred, and MEF-positive AOM caused
by nontypable H. inﬂuenzae, a secondary endpoint of the
study, was 35.3% [4, 30]. PCV11-PD is conjugated to
a cell-surface protein of H. inﬂuenzae [30], whereas the
other vaccines were conjugated to CRM197, the nontoxicInternational Journal of Otolaryngology 13
diphtheria toxin analogue (PCV7-CRM), or to OMPC, the
meningococcal outer-membrane protein complex (PCV7-
OMPC). Although direct protection against NTHi might
have added to PVC11-PD overall vaccine eﬃcacy in POET
[20], protection against NTHi AOM in populations vacci-
nated uniquely with PCV7-CRM has been demonstrated.
Data compiled from the emergency department visit-based
study in Greece conducted in an 8-year period in children
aged 0 to 14 years with AOM events complicated by
otorrhea (i.e., MEF cultures from spontaneous draining
AOM) found that there were statistically signiﬁcant declines
in the rates of otorrhea due to H. inﬂuenzae (−20%), as
well as pneumococcal otorrhea (−48%), and overall visits
(−38%)[28].Withrespecttotherandomizedcontrolledtrial
in Sweden [29], in addition to the reduction in emergency
visits, there were also statistically signiﬁcant reductions
in AOM episodes (−38%) and ventilation tube insertions
(−50%) in children. This study had a particular design as it
was a clinical trial of children identiﬁed to already be at high
risk of rAOM because of a ﬁrst episode before the age of 6
months, who were then vaccinated appropriately according
to age with a follow-up period that began 4 weeks after the
ﬁrst vaccination (at approximately 8 months of age) and
continued until the child was 2 years of age; therefore, the
results of AOM episodes, emergency department visits, or
ventilationtubeinsertionsamongyoungchildrenwithahigh
risk for recurrent AOM may be diﬀerent for AOM among
generally healthy infants, for example.
These improvements demonstrated that the availability
of PCV7-CRM vaccination has crucial implications for mor-
bidity from childhood illness and for the direct and indirect
costs of medical care. In the USA, PCV7-CRM vaccination
of infants and young children has resulted in a calculated
32% decrease in average annual spending related to AOM
visits between a prevaccination (1997 to 1999) and a post-
vaccination (2001 to 2004) period, savings of almost a half
billion US dollars each year [21]. Compared with the years
1997 to 1999 (before vaccination became routine), antibiotic
prescriptions related to AOM decreased by 42% in 2004
[21]. Approximately 2 years after widespread introduction
of PCV7-CRM in the NCKP-healthcare system, for instance,
the percentage of penicillin-resistant (minimum-inhibitory
concentration ≥2µg/mL) pneumococcal isolates among all
ages decreased from a high of 15% in 2000 to 5% in mid-
2003 [31]. Judicious use of antibiotics could be expected to
maintain these gains.
PCV7-CRM was ﬁrst approved in 2000 in USA (Prevnar;
Pﬁzer [Philadelphia, PA, USA]) for active immunization
in infants and children against IPD and pneumococcal
otitis media caused by the serotypes in the vaccine, and
it was approved in 2001 in the European Union (Preve-
nar) for active immunization against vaccine-serotype IPD
in infants and children, subsequently also encompassing
noninvasive pneumococcal infections, pneumonia and otitis
media, caused by the serotypes targeted by the vaccine
[11, 32]. The PCV11-PD studied in POET was a prototype
vaccine that was not submitted for licensure, but a 10-
valent vaccine (PCV10), based on PCV11-PD and covering
the same serotypes as PCV7-CRM plus serotypes 1, 5, and
7F, uses a mixed conjugate protein technology and was
ﬁrst licensed in the European Union in 2009 (Synﬂorix;
GlaxoSmithKline [Rixensart, Belgium]) for active immu-
nization against vaccine-serotype IPD and otitis media in
infants and children caused by the serotypes targeted by the
vaccine [30]. A 13-valent vaccine (PCV13-CRM) approved
in 2010 in the USA (Prevnar 13, Pﬁzer) and in the European
Union (Prevenar 13, Pﬁzer) for active immunization in
infants and children against IPD, pneumococcal pneumonia,
and pneumococcal otitis media caused by the serotypes
in the vaccine, which covers serotypes included in PCV7-
CRM plus serotypes 1, 3, 5, 6A, 7F, and 19A [33]. To
date, no otitis media-eﬃcacy studies or post-introduction
surveillanceotitismediaeﬀectivenessstudieswiththePCV10
or PCV13-CRM have been published.
In conclusion, otitis media is a common childhood
disease with potentially serious consequences for those
children aﬄicted with recurrent or severe manifestations.
Its prevention holds the potential to produce widespread
reductions in morbidity, antibiotic use (including the associ-
ated acquisition of resistance), and healthcare expenditures.
Although the PCV7-CRM vaccine appears to have had an
impact on otitis media morbidity since its introduction
into national immunization programs (such as in the USA
[21, 22, 24–26], Italy [27], or Greece [28]), otitis media
continues to be an issue due to changing microbiology and
other factors. If the newer vaccines, PCV10 or PCV13-CRM,
demonstrate a further impact in clinical trials or in post-
introduction surveillance against microbiologically con-
ﬁrmed otitis media (e.g., pneumococcal otitis media, vaccine
serotype-pneumococcal otitis media, or otitis media due to
other otopathogens), clinical otitis media (e.g., otitis media
episodes, recurrent otitis media, or risk of tympanostomy-
tube placement), or both, they will be valuable additions in
the eﬀort to prevent this widespread childhood disease.
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